NASDAQ · IKNA
Ikena Oncology, Inc.
Healthcare · Biotechnology
$17.16
Up+$15.79 (+1152.55%)
Updated Sep 16, 2026, 7:21 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 718.82M
- P/E ratio
- -26.94
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 457.26K
- Avg. volume
- 18K
Price performance
IKNA price history
1M range · 0 trading sessions · Daily adjusted prices
IKNA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest IKNA news
The latest Smart Investors Daily articles mentioning IKNA.
Stock researchCompany · Overview
IKNA research
Overview
Company profile and research snapshot.
Company profile
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 25, 2025 | Wedbush | Neutral | — |
| Nov 11, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2024 | HC Wainwright & Co. | Buy | — |
| May 29, 2024 | Wedbush | Neutral | — |
| May 29, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.
